CAS 179324-69-7

Bortezomib

Descrizione:

Bortezomib è un inibitore del proteasoma utilizzato principalmente nel trattamento del mieloma multiplo e di alcuni tipi di linfoma. È un composto sintetico che appartiene alla classe dei derivati dell'acido borico. La formula chimica di Bortezomib è C19H25BoroN4O4 e presenta un atomo di boro che gioca un ruolo cruciale nel suo meccanismo d'azione, che implica l'inibizione del proteasoma, un complesso cellulare responsabile della degradazione delle proteine ubiquitinate. Questa inibizione porta all'accumulo di fattori pro-apoptotici e regolatori del ciclo cellulare, inducendo infine l'apoptosi nelle cellule tumorali. Bortezomib viene somministrato tramite iniezione endovenosa o sottocutanea ed è noto per i suoi effetti collaterali, che possono includere neuropatia periferica, problemi gastrointestinali e tossicità ematologiche. La sua farmacocinetica prevede un rapido assorbimento e distribuzione, con una emivita che consente schemi di dosaggio efficaci. In generale, Bortezomib rappresenta un significativo progresso nella terapia mirata contro il cancro, mostrando il potenziale delle piccole molecole nel trattamento delle neoplasie ematologiche.

Formula: C₁₉H₂₅BN₄O₄

InChI: InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1

InChI key: InChIKey=GXJABQQUPOEUTA-RDJZCZTQSA-N

SMILES: [C@H](CC1=CC=CC=C1)(C(N[C@@H](CC(C)C)B(O)O)=O)NC(=O)C=2C=NC=CN2

Sinonimi:

• B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
• Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
• Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-
• Boronic acid, [3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-, [S-(R*,S*)]-
• Bortezomib for research
• Bortizomib
• Brotezamide
• Dpba
• Ldp 341
• Mg 341
• Mln 341
• N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
• N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide
• NSC 681239
• PS 341 (pharmaceutical)
• Ps 314
• Ps 341
• Radiciol
• Velcade

Bortezomib

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Purezza: >98.0%(HPLC)

Colore e forma: White to Almost white powder to crystal

Peso molecolare: 384.24

Ref: 3B-B5741

Bortezomib, 98%

CAS: 179324-69-7

Bortezomib, 179324-69-7, is a peptidic boronic acid analog and antineoplastic agent which turns off cell signaling pathways through 26S proteasome inhibition. Learn more.

Formula: C₁₉H₂₅BN₄O₄

Purezza: 98%

Colore e forma: Powder or crystals or crystalline powder, White to off-white

Peso molecolare: 384.24

Ref: 02-J60378

Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Purezza: 98%

Colore e forma: Solid

Peso molecolare: 384.2372

Ref: IN-DA0026XG

Bortezomib

CAS: 179324-69-7

Bortezomib

Purezza: ≥95%

Peso molecolare: 384.24g/mol

Ref: 54-BUP15505

Bortezomib

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Purezza: ≥ 98.0%

Colore e forma: White to off-white powder or solid

Peso molecolare: 384.24

Ref: 7W-GP0262

Bortezomib

CAS: 179324-69-7

Bortezomib

Formula: C₁₉H₂₅BN₄O₄

Purezza: 98% (nmr) (Typical Value in Batch COA)

Colore e forma: white solid

Peso molecolare: 384.24g/mol

Ref: 54-BISN0125

Bortezomib [Optimized for Cell Culture]

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Purezza: >98.0%(HPLC)

Colore e forma: White to Almost white powder to crystal

Peso molecolare: 384.24

Ref: 3B-B6775

Bortezomib

CAS: 179324-69-7

Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective.

Formula: C₁₉H₂₅BN₄O₄

Purezza: 97.79% - >99.99%

Colore e forma: Yellow Solid

Peso molecolare: 384.24

Ref: TM-T2399

(1R,2S)-Bortezomib

CAS: 179324-69-7

Formula: C₁₉H₂₅BN₄O₄

Peso molecolare: 384.24

Ref: 4Z-B-4697

Bortezomib-D8 (Major)

Prodotto controllato

CAS: 179324-69-7

Applications Labelled Bortezomib, which the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.d6-3%d7-10%d8-86%
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)

Formula: C₁₉H₁₇D₈BN₄O₄

Colore e forma: Off-White

Peso molecolare: 392.29

Ref: TR-B675702

Bortezomib

Prodotto controllato

CAS: 179324-69-7

Stability Hygroscopic and Moisture Sensitive
Applications Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009);

Formula: C₁₉H₂₅BN₄O₄

Colore e forma: White To Off-White

Peso molecolare: 384.24

Ref: TR-B675700

Bortezomib

CAS: 179324-69-7

Selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.

Formula: C₁₉H₂₅BN₄O₄

Purezza: Min. 95%

Colore e forma: White Powder

Peso molecolare: 384.24 g/mol

Ref: 3D-FM19000

Bortezomib - Bio-X ™

CAS: 179324-69-7

Bortezomib is a selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating t-cell lymphomas and multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.

Formula: C₁₉H₂₅BN₄O₄

Purezza: Min. 95%

Colore e forma: Powder

Peso molecolare: 384.24 g/mol

Ref: 3D-BB164258

Bortezomib

CAS: 179324-69-7

Purezza: 98%

Peso molecolare: 384.24

Ref: 10-M06307